• Pilar de la Morena Barrio, María Ángeles Vicente Conesa, Enrique González-Billalabeitia, Edgar Urrego, Elisa García-Garre, Elena García-Martínez, Marta Zafra Poves, Vicente Vicente, and de la PeñaFrancisco AyalaFAFrom the Department of Hematology and Medical Oncology, University Hospital Morales Meseguer, Avda Marques de los Velez, and Centro Regional de Hemodonación, Murcia, Spain..
• From the Department of Hematology and Medical Oncology, University Hospital Morales Meseguer, Avda Marques de los Velez, and Centro Regional de Hemodonación, Murcia, Spain.
• J Natl Compr Canc Netw. 2015 Apr 1; 13 (4): 417-23.

PurposeAlthough diabetes mellitus (DM) is recognized as a risk factor for chemotherapy-induced neurotoxicity, its true impact on intensity and time course of peripheral neuropathy is still unclear. The goal was to analyze the relevance of preexisting DM to weekly paclitaxel-induced peripheral neuropathy (PIPN).MethodsWe performed a retrospective case-control study (1:2) including a total of 129 patients with breast cancer (43 with DM and 86 controls) treated with single-agent weekly paclitaxel (wP).ResultsCompared with controls, patients with DM treated with wP experienced PIPN more frequently (74.4% vs 58.4%; P=.016) and with higher severity (grade 2-3: 51.2% vs 27.7%; P=.014). A significant delay in PIPN resolution was observed in women with DM (P=.001) and, in a multivariate analysis, DM was the only independent predictor for delayed recovery (hazard ratio [HR], 0.16; 95% CI, 0.05-0.55; P=.003). After 2 years, 68.7% of patients with DM (vs 29.2% of women without DM) still experienced PIPN, which was functionally significant (grade 2-3) in 18.2%.ConclusionsSignificantly more dose delays and reductions because of PIPN occurred in patients with DM. Preexisting DM associates with long-lasting significant PIPN in patients treated with wP. Benefits and risks of long-term significant PIPN should be carefully balanced in patients with DM before starting wP chemotherapy.Copyright © 2015 by the National Comprehensive Cancer Network.

25 keywords...

hide…